Consequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs)...

How does #toxicity from #immunotherapy affect the real world patient?
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.

www.tandfonline.com/doi/full/10....

Long-Term Toxicity of Immune Checkpoint Inhibitors This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...

Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com

Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship

#CancerCentreIre @oncoalert.bsky.social #LCSM
jamanetwork.com/journals/jam...

Interview with Dr. Bryant Lin: Teaching My Lung Cancer | IASLC In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Dr. Bryant Lin, Clinical Professor of Medicine at Stanford University and co-founder ...

After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care.

🎧 Listen: bit.ly/LinTMLC

ASCO and Google Cloud have introduced an AI-powered tool designed to streamline cancer care documentation, with potential to reduce administrative burden and improve workflow.
🔗 ascopost.com/news/may-202...
#Oncology #HealthIT

I går stod vi sammen. På tribunen. På banen. I hjertet. Takk💛

Blir du med @glimtivest.bsky.social på historiens aller første @bodoglimt.bsky.social Kvinner-kamp på Brann stadion i morgen, så vanker det stickers 🙏

Elsker dette 💛🌿🕊️!!!

Avreise til Athen 🇬🇷

Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...

Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social
- First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states
- Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro

@oncoalert.bsky.social @kraskickers.bsky.social #LCSM

aacrjournals.org/cancerdiscov...

Text reads: Stand with refugees and people forced from home. Stand with people demanding access to safe abortion care. Stand with people whose health is impacted by climate change. Stand with people facing health inequities due to racism and discrimination. Stand with vulnerable people everywhere.

Hi Bluesky community! We're excited to be here to share important humanitarian stories.

Would you let your network know where to find us? This is just a snapshot of what we stand for as an emergency medical organization:

AACR Cancer Disparities Progress Report: Clinical trials are critical to determining the safety and efficacy of new treatments, but limited diversity among participants hinders progress in cancer care for all patient populations. https://buff.ly/3XgMcoh

kaplan-meier curves showing (A) equivalent PFS for mobocertinib and chemotherpy (C) improved duration of response for mobocertinib

Full publication of phase 3 that compared mobocertinib to platinum-pem in EGFR exon 20 lung cancer. Ultimately led to mobocertinib removal from market. This remains the goal: new drugs should be better than chemotherapy. We should not settle for adding to chemotherapy!
ascopubs.org/doi/pdf/10.1...

Love Dr. Burstein caveat to this slide...but does suggest that maybe the sweet spot 🎯 is:

BOTH - 1️⃣ CDK switch (and continued blockade) AND 2️⃣ novel next-gen endocrine agent.

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

𝗞𝗔𝗠𝗣𝗗𝗔𝗚

🏆 Europa League
🗓️ Kampdag 5
🆚 Manchester United
🕕 21:00 CET
🏟️ Old Trafford
ℹ️ glimt.no
📺 Viaplay
📻 Radio 3 Bodø

Slik starter Glimt i Manchester 🤩

Only a subset of patients respond to immunotherapy

Why? Which ones?

We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.

www.nature.com/articles/s41...

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc

doi.org/10.1093/jnci...

New article in MIT Sloan Management Review shows how leaders who influence through collaboration get better outcomes from decisions than leaders who try to "sell" their ideas. Getting the support of others without formal authority works better than persuasion:
sloanreview.mit.edu/article/why-...
.

#FollowFriday: Thank you to the community for your incredible support and for helping us grow!

This is the first Friday since our recent spike in followers, we’d like to highlight a few of our staff profiles for you to explore and follow.

Keep reading to learn more about some of our staff. 🧵⤵️

www.ntog.org#events

Thrilled to attend #onkologiskforum2024 Bergen, Norway! Today kick off with great session at @NLCG (Norwegian Lung Cancer Group) discussing national Lung cancer screening, MDT, exciting clinical trials and news from Nordic Thoracic Oncology Group, ntog.org! 🤍

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the ...

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM

Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice

ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM

ascopubs.org/doi/10.1200/...

Is sharing our writing a thing here? 😊
Proud of this piece because it represents the work of so many trying to make medicine and communication better for our patients. #MedSky
www.mayoclinicproceedings.org/action/showP...

Superb opinion piece on PCI in SCLC: do we need it in the IO era?

Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms

#LCSM #MedSky #OncSky

www.sciencedirect.com/science/arti...

Matching patients to clinical trials with large language models - Nature Communications Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social:

- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial

Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...

Thank you🙏🏼🤍! From oncologist in Northern Norway

Happy to present our review on facilitators and barrieres for implementing digital #ePRO in routine #cancer care- in #ESMO Real World Data and Digital Oncology! Open access link here - www.esmorwd.org/action/showP...